Home Compare GILD vs ROG.SW
Stock Comparison · Industry comparison · Drug Manufacturers - General

Gilead Sciences vs Roche Holding: Which Stock Looks Stronger in 2026?

Gilead Sciences holds the cleaner structural position, with the lead spread across valuation and stability. Roche still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in valuation, but stability adds another real layer to the result.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GILD and ROG.SW share the same industry classification.

For a similarity-based comparison, see how Gilead Sciences and Roche each position within their functional peer groups in AssetNext.

Peer-Relative Score
GILD
Gilead Sciences, Inc.
70
Peer-Score
Signal qualityHigh
vs
ROG.SW
Roche Holding AG
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: GILD vs ROG.SW Profitability 79 75 Stability 65 51 Valuation 83 64 Growth 44 55 GILD ROG.SW
Gap Ranking
#1 Valuation +19
#2 Stability +14
#3 Growth +11
#4 Profitability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GILD and ROG.SW Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GILDROG.SW Relative valuation Structural strength

Structure stays fairly close here, while current pricing still looks more supportive for Gilead Sciences, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
Both profiles are strong on valuation, but Gilead Sciences, Inc. leads clearly.
Stability
On stability, the same pattern holds: both rank well, but Gilead Sciences, Inc. still sits higher.
Valuation — Dominant Gap
GILD
83
ROG.SW
64
Gap+19in favour of GILD

The main spread comes from a meaningfully cheaper peer-relative valuation.

What keeps the gap from being one-sided

Earnings growth also leans the other way, which keeps the score lead from reading as a full growth sweep.

What this means for the comparison

The lead is built on both valuation and stability — though growth still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the GILD vs ROG.SW comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-and-stability comparisons

Explore how GILD and ROG.SW each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.